University of Wisconsin-Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination -- including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.
Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture.
Researchers have shown that a variation in the viral genome of Covid-19 improved its ability to infect human cells and helped it become the dominant strain circulating around the world today.
Infecting volunteers with COVID-19 may provide valuable insights for future rounds of vaccine testing, but would require very strict controls and is unlikely to advance the current slate of vaccines in advanced development, argues a group of infectious disease experts. Though model development would be laborious, it could ultimately be advantageous, allowing researchers to answer a broader range of questions about both the virus and vaccines designed to prevent it during later rounds of testing.
In a Perspective for the New England Journal of Medicine, members of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for human challenge studies, to support SARS-CoV-2 vaccine development.
Research from the University of Bath in the UK suggests the best medicine-related support comes from hospital pharmacists, yet few discharged patients use helplines set up for this purpose.
Experiments in mice have shown early success in vaccinating them against potentially deadly bacterial infections, such as methicillin-resistant Staphylococcal aureus, or MRSA, the strain resistant to most drug treatments.
A UCLA-led study has found that in 2 of 3 states and jurisdictions with policies that require students entering school to receive the human papillomavirus vaccine, vaccination rates among 13-to-17-year-olds were significantly higher than in surrounding states without such policies.
A new study from researchers at La Jolla Institute for Immunology (LJI) and Erasmus University Medical Center (Erasmus MC) shows that even the sickest COVID-19 patients produce T cells that help fight the virus. The study offers further evidence that a COVID-19 vaccine will need to elicit T cells to work alongside antibodies.
Using DNA origami as a virus-like scaffold, MIT researchers designed an HIV-like particle that provokes a strong response from human immune cells grown in the lab. They are now testing this approach as a potential vaccine candidate in live animals, and adapting it to SARS-CoV-2, as well as other pathogens.